Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C

Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Hiromasa Ishii, Kazuo Kashiwazaki, Jiro Nishida, Takeshi Yoshida, Shigeyuki Zeki, Hideo Yoshida, Masahiro Yoshioka, Yasutaka Inagaki, Naoki Kumagai, Toshifumi Hibi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We examined therapeutic superiority of induction therapy with twice-daily IFN-β (3X2=6 million units/day) onto 6-months consensus interferon monotherapy for chronic hepatitis C. Patients were randomly assigned to monotherapy without (group I, n=16) and with induction therapy (group II, n=12). The mean age of group II was older than that of group I, and other baseline condition was not statistically significant. Sustained virological response (SVR) rates of group I and II were 81.3% (13/16) and 58.3% (7/12), respectively (p=0.365). SVR rates in patients with genotype 1b were 66.7% (4/6) and 0% (0/2, because of drop-out), and those with high viral load were 70% (7/10) and 75% (6/8) in group I and II, respectively (p=1.000). Drop-out rates during therapy were 6.3% (1/16) and 33.3% (4/12) in group I and II, respectively (p=0.176). Age less than 50 years was the only independent factor that was shown by multivariate logistic model analysis to be associated with a sustained virological response. Although randomization failed to produce and equal age distribution in the two groups in this study, our results suggest that induction therapy with twice-daily IFN-β has no beneficial effect on the efficacy of monotherapy with consensus interferon, probably because of the higher drop-out rates and incidence of adverse reactions with induction therapy.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalKeio Journal of Medicine
Volume55
Issue number3
DOIs
Publication statusPublished - 2006

Fingerprint

Interferon-beta
Chronic Hepatitis C
Interferons
Therapeutics
Age Distribution
Group Psychotherapy
Random Allocation
Viral Load
Age Groups
Logistic Models
Genotype
Incidence

Keywords

  • Consensus interferon
  • Induction therapy
  • Interferon-beta
  • Monotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. / Saito, Hidetsugu; Tada, Shinichiro; Ebinuma, Hirotoshi; Ishii, Hiromasa; Kashiwazaki, Kazuo; Nishida, Jiro; Yoshida, Takeshi; Zeki, Shigeyuki; Yoshida, Hideo; Yoshioka, Masahiro; Inagaki, Yasutaka; Kumagai, Naoki; Hibi, Toshifumi.

In: Keio Journal of Medicine, Vol. 55, No. 3, 2006, p. 111-117.

Research output: Contribution to journalArticle

Saito, H, Tada, S, Ebinuma, H, Ishii, H, Kashiwazaki, K, Nishida, J, Yoshida, T, Zeki, S, Yoshida, H, Yoshioka, M, Inagaki, Y, Kumagai, N & Hibi, T 2006, 'Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C', Keio Journal of Medicine, vol. 55, no. 3, pp. 111-117. https://doi.org/10.2302/kjm.55.111
Saito, Hidetsugu ; Tada, Shinichiro ; Ebinuma, Hirotoshi ; Ishii, Hiromasa ; Kashiwazaki, Kazuo ; Nishida, Jiro ; Yoshida, Takeshi ; Zeki, Shigeyuki ; Yoshida, Hideo ; Yoshioka, Masahiro ; Inagaki, Yasutaka ; Kumagai, Naoki ; Hibi, Toshifumi. / Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. In: Keio Journal of Medicine. 2006 ; Vol. 55, No. 3. pp. 111-117.
@article{394f9b0bcf1a47c485d808dabd07da7d,
title = "Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C",
abstract = "We examined therapeutic superiority of induction therapy with twice-daily IFN-β (3X2=6 million units/day) onto 6-months consensus interferon monotherapy for chronic hepatitis C. Patients were randomly assigned to monotherapy without (group I, n=16) and with induction therapy (group II, n=12). The mean age of group II was older than that of group I, and other baseline condition was not statistically significant. Sustained virological response (SVR) rates of group I and II were 81.3{\%} (13/16) and 58.3{\%} (7/12), respectively (p=0.365). SVR rates in patients with genotype 1b were 66.7{\%} (4/6) and 0{\%} (0/2, because of drop-out), and those with high viral load were 70{\%} (7/10) and 75{\%} (6/8) in group I and II, respectively (p=1.000). Drop-out rates during therapy were 6.3{\%} (1/16) and 33.3{\%} (4/12) in group I and II, respectively (p=0.176). Age less than 50 years was the only independent factor that was shown by multivariate logistic model analysis to be associated with a sustained virological response. Although randomization failed to produce and equal age distribution in the two groups in this study, our results suggest that induction therapy with twice-daily IFN-β has no beneficial effect on the efficacy of monotherapy with consensus interferon, probably because of the higher drop-out rates and incidence of adverse reactions with induction therapy.",
keywords = "Consensus interferon, Induction therapy, Interferon-beta, Monotherapy",
author = "Hidetsugu Saito and Shinichiro Tada and Hirotoshi Ebinuma and Hiromasa Ishii and Kazuo Kashiwazaki and Jiro Nishida and Takeshi Yoshida and Shigeyuki Zeki and Hideo Yoshida and Masahiro Yoshioka and Yasutaka Inagaki and Naoki Kumagai and Toshifumi Hibi",
year = "2006",
doi = "10.2302/kjm.55.111",
language = "English",
volume = "55",
pages = "111--117",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "3",

}

TY - JOUR

T1 - Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C

AU - Saito, Hidetsugu

AU - Tada, Shinichiro

AU - Ebinuma, Hirotoshi

AU - Ishii, Hiromasa

AU - Kashiwazaki, Kazuo

AU - Nishida, Jiro

AU - Yoshida, Takeshi

AU - Zeki, Shigeyuki

AU - Yoshida, Hideo

AU - Yoshioka, Masahiro

AU - Inagaki, Yasutaka

AU - Kumagai, Naoki

AU - Hibi, Toshifumi

PY - 2006

Y1 - 2006

N2 - We examined therapeutic superiority of induction therapy with twice-daily IFN-β (3X2=6 million units/day) onto 6-months consensus interferon monotherapy for chronic hepatitis C. Patients were randomly assigned to monotherapy without (group I, n=16) and with induction therapy (group II, n=12). The mean age of group II was older than that of group I, and other baseline condition was not statistically significant. Sustained virological response (SVR) rates of group I and II were 81.3% (13/16) and 58.3% (7/12), respectively (p=0.365). SVR rates in patients with genotype 1b were 66.7% (4/6) and 0% (0/2, because of drop-out), and those with high viral load were 70% (7/10) and 75% (6/8) in group I and II, respectively (p=1.000). Drop-out rates during therapy were 6.3% (1/16) and 33.3% (4/12) in group I and II, respectively (p=0.176). Age less than 50 years was the only independent factor that was shown by multivariate logistic model analysis to be associated with a sustained virological response. Although randomization failed to produce and equal age distribution in the two groups in this study, our results suggest that induction therapy with twice-daily IFN-β has no beneficial effect on the efficacy of monotherapy with consensus interferon, probably because of the higher drop-out rates and incidence of adverse reactions with induction therapy.

AB - We examined therapeutic superiority of induction therapy with twice-daily IFN-β (3X2=6 million units/day) onto 6-months consensus interferon monotherapy for chronic hepatitis C. Patients were randomly assigned to monotherapy without (group I, n=16) and with induction therapy (group II, n=12). The mean age of group II was older than that of group I, and other baseline condition was not statistically significant. Sustained virological response (SVR) rates of group I and II were 81.3% (13/16) and 58.3% (7/12), respectively (p=0.365). SVR rates in patients with genotype 1b were 66.7% (4/6) and 0% (0/2, because of drop-out), and those with high viral load were 70% (7/10) and 75% (6/8) in group I and II, respectively (p=1.000). Drop-out rates during therapy were 6.3% (1/16) and 33.3% (4/12) in group I and II, respectively (p=0.176). Age less than 50 years was the only independent factor that was shown by multivariate logistic model analysis to be associated with a sustained virological response. Although randomization failed to produce and equal age distribution in the two groups in this study, our results suggest that induction therapy with twice-daily IFN-β has no beneficial effect on the efficacy of monotherapy with consensus interferon, probably because of the higher drop-out rates and incidence of adverse reactions with induction therapy.

KW - Consensus interferon

KW - Induction therapy

KW - Interferon-beta

KW - Monotherapy

UR - http://www.scopus.com/inward/record.url?scp=33749637193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749637193&partnerID=8YFLogxK

U2 - 10.2302/kjm.55.111

DO - 10.2302/kjm.55.111

M3 - Article

C2 - 17008803

AN - SCOPUS:33749637193

VL - 55

SP - 111

EP - 117

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 3

ER -